Vaccines and Global Health: The Week in Review
21 January 2023 :: Issue 687
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
CEPI and Institut Pasteur de Dakar [IPD] announce 10-year partnership to boost manufacturing of affordable vaccines for the Global South

- Partnership will advance equitable access to vaccines by expanding IPD’s capacity to produce routine immunization vaccines across multiple technologies, and reserve capacity to rapidly supply vaccines to Global South countries during disease outbreaks.
- Collaboration will see CEPI invest up to $50 million over 10 years.
- IPD joins CEPI’s global manufacturing network which will support agile and resilient manufacturing in the Global South – boosting and accelerating access to life-saving vaccines during future outbreaks and pandemics.

19 January 2022; OSLO, Norway and DAKAR, Sénégal:
The Coalition for Epidemic Preparedness Innovations (CEPI) and the Institut Pasteur de Dakar (IPD) today announced a partnership that will advance equitable access to vaccines in Africa and contribute to the African Union’s goal of increasing African manufacturers’ share of vaccine supply to the continent to 60% by 2040. The collaboration will boost the manufacturing of affordable vaccines at IPD’s facilities in Dakar, and reserve capacity to produce vaccines specifically for Global South countries during future outbreaks and pandemics to combat the kind of inequity that characterised the response to COVID-19.

CEPI is creating a new network of vaccine manufacturers in Global South countries to substantially increase the world’s capacity and capability to produce vaccines against emerging outbreaks and pandemic threats. IPD becomes part of this network, having manufactured WHO prequalified yellow fever vaccines for 80 years, and with the ambition to become a regional manufacturing hub making vaccines in Africa, for Africa, through Project MADIBA[1].

IPD will initially receive up to US$15 million in grant funding over three years, with the option to extend the partnership’s scope and funding to a total of up to US$50 million over 10 years. CEPI’s investment will complement that of other major funders for MADIBA, including the European Union, European Investment Bank, the Agence Française de Développement, the Islamic Development Bank, the International Finance Corporation, the U.S. International Development Finance Corporation, the Government of Germany and the Government of Sénégal.

The first phase of the partnership will support the development and sustainability of IPD’s manufacturing facilities for routine and outbreak vaccinations across multiple vaccine technologies and prepare them to begin supplying vaccines to Global South countries within 100 days of a new pathogen being identified. This timing is key to stopping future emerging disease outbreaks from becoming pandemics. Known as the 100 Days Mission, the goal is supported by the leaders of the G7 and G20 and industry executives and is at the heart of CEPI’s plan to end pandemics....

Dr. Richard Hatchett, Chief Executive Officer, CEPI, said, “Our partnership with Institut Pasteur de Dakar aims to support agile and resilient manufacturing capacity and capability that is ready and able to respond to the threat of new disease outbreaks. IPD will be a crucial partner in our global
manufacturing network, guaranteeing CEPI-backed vaccine developers rapid access to world-class manufacturing capacity and expertise when faced with future outbreaks. Historically, a handful of countries and regions have dominated access to global vaccine supply. This needs to change if the world is to stand a chance of mounting rapid, equitable responses to future outbreak and pandemic threats. Key to achieving this mission will be the establishment of a global network of vaccine manufacturers, specifically in underserved Global South regions where many of the people most vulnerable to infectious disease outbreaks live.”

:::::::

Financing for Innovation in Immunization

The US$ 500 million challenge: Gavi launches INFUSE 2.0 to scale up innovations in immunisation

- INFUSE is an innovation scaling hub that matches investors with innovators and entrepreneurs to help scale up new ways to improve vaccination coverage in lower-income countries
- Leaders expect to secure at least US$ 500 million in private investment, alongside financial and operational commitments from Google.org, Coca-Cola Foundation & Project Last Mile and Alwaleed Philanthropies.
- “With millions more children now at risk of deadly, preventable diseases, we need to ensure the most promising, most scalable innovations reach the countries that need them, urgently. INFUSE 2.0 can do just that,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
Davos, 19 January 2023 – Gavi, the Vaccine Alliance announced today the launch of INFUSE 2.0, an innovation scaling hub to accelerate immunisation systems upgrades for the world’s most in-need countries.

INFUSE 2.0 features a collective of commercial and philanthropic investors focused on supporting global health entrepreneurs.
The initiative also introduces a first-of-its-kind digital platform to simplify connections between communities, innovators and the private sector to make it easier and faster to share expertise. Impact evaluators will also help start-ups, investors and stakeholders better track and amplify the impact of their innovations on immunisation and global health.

By 2030, INFUSE 2.0 expects to secure at least US$ 500 million in private investment to promote access to new and under-used vaccines and immunisation innovations in the fight against deadly and debilitating infectious diseases.”The pandemic has rolled back years of progress improving vaccine coverage in the world’s most vulnerable countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “With millions more children now at risk of deadly, preventable diseases, we need to ensure the most promising, most scalable innovations reach the countries that need them, urgently. INFUSE 2.0 can do just that, bringing together investors looking for impact with entrepreneurs who can deliver it to help protect children across the world.”

The new initiative builds on Innovation for Uptake, Scale and Equity in Immunisation (INFUSE) 1.0, launched in 2016, which has cultivated a community of start-up innovators overcoming vaccine delivery challenges. Initial investments in INFUSE totalled more than US$ 60 million, leading to more than US$ 200 million in follow-on funding for global health innovators...
INFUSE 2.0: Reclaiming ground in the global fight for health security

According to the United Nations, the COVID-19 pandemic erased five years of human development progress globally. Impacts to already-fragile government services in vulnerable communities resulted in the largest backslide in childhood vaccinations in three decades. Today, INFUSE 2.0 launches to address immediate country needs and brace immunisation systems against further shocks, strengthening and scaling services and solutions faster than ever before...

While the pandemic brings global health to a critical juncture, Gavi’s work stabilising disrupted health and immunisation systems is yielding promising results:

- Installing a health care credential service: Throughout Mauritania and Ethiopia, Mastercard is supporting continuity of care by enabling offline medical data storage and allowing patients to travel with this data on a Mastercard Wellness Pass chip card.
- Solving last-mile delivery: Zipline, an automated logistics and aircraft company, is pioneering on-demand drone delivery of priority products including emergency vaccines in Rwanda, Ghana, Nigeria, Kenya, Japan and India.
- Expanding health horizons: In India, Unilever and Gavi are working together to shift behaviour among parents with through handwashing, hygiene and immunisation education.

Engineering the future of immunisation system resilience

In 2023, strengthening worldwide immunisation systems through digital innovation is a priority among G7 and G20 countries. INFUSE 2.0 offers a means to introduce these innovations at scale. Within INFUSE’s unique scaling-hub experience, Gavi invites stakeholders to explore critical roles:

- Country partners surface pressing needs and challenges;
- Innovators deploy applications and insights to immunisation and health systems;
- Investors join the INFUSE Syndicate and coordinate investments to create reliable funding pathways for project scale-up;
- Corporate partners share expertise and implement solutions in varied country contexts; and
- Passionate doers engineer the digital platform and nurture next-generation social mission innovators.

Access to Medicines – Pfizer

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

01.17.2023

- Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
- Expands on the initial offering of all patented medicines and vaccines available in the U.S. or EU to now include off-patent medicines, bringing total offering from 23 to around 500 products.
- Builds on already delivered medicines and vaccines along with medical training and supply chain support to Rwanda and advanced conversations with 16 other Accord country governments for supply and health system support.
DAVOS, Switzerland--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.

Launched in May 2022, the Accord, a transformative initiative focused on greatly reducing health inequities that exist between many lower-income countries and the rest of the world, initially included a commitment from Pfizer for access to all its patented medicines and vaccines available in the U.S. or European Union on a not-for-profit basis to 45 lower-income countries. However, to better align with disease burden and unmet patient needs in these countries, Pfizer will now expand its offering under the Accord to include off-patent products, bringing the total offering from 23 products to around 500 products.

The Accord portfolio offering now includes both patented and off-patent medicines and vaccines that treat or prevent many of the greatest infectious and non-communicable disease threats faced today in lower-income countries. This includes chemotherapies and oral cancer treatments that have the potential to treat nearly one million new cancer cases in Accord countries each year1. It also includes a wide range of antibiotics, that can help to address the rising morbidity, mortality and costs associated with antimicrobial resistance (AMR) and help to prevent around 1.5 million deaths that occur each year in these countries as a result of bacterial infections in hospitals and community health clinics2. As Pfizer launches new medicines and vaccines, those products will also be included in the Accord portfolio on a not-for-profit basis.

“We launched the Accord to help reduce the glaring health equity gap that exists in our world. Our hope is to empower country governments and co-create solutions with them and other multi-sector partners to break down many of the system-level barriers to better health. In the months since the Accord’s launch, we have heard resoundingly from these leaders that access to a broader and more immediate scope of consistent, high-quality products is needed for meaningful and sustainable transformation. We believe this expansion of our product offering, combined with continued efforts to help address the barriers that limit or prevent access, will help us to achieve and even expedite our vision of a world where all people have access to the medicines and vaccines they need to live longer and healthier lives,” said Pfizer Chairman and CEO Albert Bourla...

---

**Featured Journal Content**

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 21 Jan 2023)
**Essential childhood immunization in 43 low- and middle-income countries: Analysis of spatial trends and socioeconomic inequalities in vaccine coverage**
Anna Dimitrova, Gabriel Carrasco-Escobar, Robin Richardson, Tarik Benmarhnia
Research Article | published 17 Jan 2023 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004166
This is an uncorrected proof.
Abstract
Background
Globally, access to life-saving vaccines has improved considerably in the past 5 decades. However, progress has started to slow down and even reverse in recent years. Understanding subnational heterogeneities in essential child immunization will be critical for closing the global vaccination gap.

Methods and findings
We use vaccination information for over 220,000 children across 1,366 administrative regions in 43 low- and middle-income countries (LMICs) from the most recent Demographic and Health Surveys. We estimate essential immunization coverage at the national and subnational levels and quantify socioeconomic inequalities in such coverage using adjusted concentration indices. Within- and between-country variations are summarized via the Theil index. We use local indicator of spatial association (LISA) statistics to identify clusters of administrative regions with high or low values. Finally, we estimate the number of missed vaccinations among children aged 15 to 35 months across all 43 countries and the types of vaccines most often missed. We show that national-level vaccination rates can conceal wide subnational heterogeneities. Large gaps in child immunization are found across West and Central Africa and in South Asia, particularly in regions of Angola, Chad, Nigeria, Guinea, and Afghanistan, where less than 10% of children are fully immunized. Furthermore, children living in these countries consistently lack all 4 basic vaccines included in the WHO’s recommended schedule for young children. Across most countries, children from poorer households are less likely to be fully immunized. The main limitations include subnational estimates based on large administrative divisions for some countries and different periods of survey data collection.

Conclusions
The identified heterogeneities in essential childhood immunization, especially given that some regions consistently are underserved for all basic vaccines, can be used to inform the design and implementation of localized intervention programs aimed at eliminating child suffering and deaths from existing and novel vaccine-preventable diseases.

:::
:::
:::

Health – Global Health Equity

39 Organizations Pledge to Close Gaps on Global Health Equity
19 Jan 2023
- World Economic Forum leads launch of a first-in-kind global health equity pledge to create a healthier and fairer world
- Innovative Zero Health Gaps Pledge will counter growing global disparities by mobilizing executive leadership to prioritize health equity action throughout their organizations
- Some 39 organizations from nine countries committed to join the Forum on its new journey
- Learn more about the Global Health Equity Network here; Read the Zero Health Gaps Pledge here; Watch the Zero Health Gaps Pledge press conference live stream recording here

Davos-Klosters, Switzerland, 19 January 2023 – Some 39 organizations today signed the Global Health Equity Network Zero Health Gaps Pledge at the World Economic Forum Annual Meeting 2023 in Davos and committed to take concerted action to advance health equity globally. The pledge includes 10 key commitments all signatories have made to embed health equity principles throughout their operations, workforce and guiding philosophies. It marks the beginning of an historic journey to making health
equity an integral part of business strategies globally and an important step towards a world without health disparities.

The Zero Health Gaps Pledge is part of the Global Health Equity Network, which brings together key stakeholders from the public and private sectors to advance a collective vision of zero health gaps, in line with the UN Sustainable Development Goals. This innovative pledge is a public statement from its members declaring their commitment to take concrete steps to improve health equity across sectors and geographies and to help build a resilient and inclusive global economy that drives value for all... he pledge is a direct response to the persistent and growing global health disparities between and within countries. The difference in average life expectancy at birth between high- and low-income countries is glaring at 78 and 64 years respectively. At the most extreme, Japan and the Central African Republic have a difference in average life expectancy of over 30 years. Global climate and health crises, including the COVID-19 pandemic, have heightened both the severity of these inequities and the potential consequences of inaction. The Zero Health Gaps Pledge is a pledge to take action today so we can reverse this reality tomorrow.

The full list of Zero Health Gaps Pledge signatories as of 19 January 2023:
(RED)
Acolade, Inc.
Agility
American Cancer Society
American Heart Association
AmerisourceBergen
Anglo American
AstraZeneca
Black Directors Health Equity Agenda
Boston Medical Center
Burjeel Holdings
Cityblock Health
Color Health
Deloitte
Elevance Health
Fresenius Medical Care
Gavi, the Vaccine Alliance
Global Partnerships Forum
Hackensack Meridian Health
HarbourView Equity Partners
HealthTech4Medicaid
Henry Schein
Hologic, Inc.
Huma
Kaiser Permanente
Medtronic
Mission Measurement
MSD
PATH
Pfizer
Royal Philips
The Zero Health Gaps Pledge
Global Health Equity Network
January 2023

All organizations have a role to play in advancing health equity and eliminating disparities in health and wellbeing outcomes between and within countries. The Zero Health Gaps Pledge is a commitment from CEOs across industries and regions for their organizations to play their part by embedding health equity in core strategies, operations and investments.

We pledge to:
1. Continually seek to understand how our organization can help address the root causes of health inequities and create a positive health equity impact.

2. Assess our own organization’s health equity impact across our workforce (e.g., employee workplace health exposures), offerings and services (e.g., quality and accessibility for underserved populations), communities (e.g., investments in community health) and ecosystems (e.g., health equity promotion through advocacy and public statements).

3. Consistently seek to understand health equity needs across our workforce, consumer base, communities, and ecosystem to make strategic decisions, inclusive of investments, and use insights to inform our organization’s choices from strategy to execution.

4. Measure the impact of our health equity efforts, such as health and wellbeing benefits, in ways that identify variations between and across groups, and use insight to inform decisions.

5. Seek to employ ethical use of data and strong privacy controls.

6. Look for opportunities to share progress externally, including potentially as a part of ESG and other sustainability reporting.

7. Establish and strengthen accountability systems within our organization by creating an environment where lessons can be shared and scaled, including having health equity as an agenda item at board meetings.

8. Collaborate with communities to identify key health equity needs and identify potential solutions, and to measure impact.
9. Inspire other organizations across sectors to act, to share learnings and collective investment decisions, and to accelerate the work of the GHEN and beyond.

10. Support the creation of a concrete, measurable roadmap with achievable global milestones towards health equity.

The GHEN is committed to convening leaders to help build a resilient and inclusive global economy that drives value for all. This pledge is a public statement from signatories that they are committed to help improve health equity and to embed health equity principles across their organizations. Each signatory is at a different stage of their health equity journey, so this pledge harnesses energy from across sectors and geographies to achieve a world with Zero Health Gaps.

Business Case for Health Equity
All organizations have a role to play - and a material interest - in advancing health equity. Learn more about why investing in health equity is good for business.

Action Guide for Advancing Health Equity
All organizations can leverage their platforms to support health equity across their entire value chain. Learn more about what actions your organization can take to have the greatest impact.

COVID – China Focus

China says COVID outbreak has infected 80% of population
BEIJING, Jan 21 (Reuters) - The possibility of a big COVID-19 rebound in China over the next two or three months is remote as 80% of people have been infected, a prominent government scientist said on Saturday.

The mass movement of people during the ongoing Lunar New Year holiday period may spread the pandemic, boosting infections in some areas, but a second COVID wave is unlikely in the near term, Wu Zunyou, chief epidemiologist at the China Center for Disease Control and Prevention, said on the Weibo social media platform.

Hundreds of millions of Chinese are travelling across the country for holiday reunions that had been suspended under recently eased COVID curbs, raising fears of fresh outbreaks in rural areas less equipped to manage large outbreaks.

China has passed the peak of COVID patients in fever clinics, emergency rooms and with critical conditions, a National Health Commission official said on Thursday.

Nearly 60,000 people with COVID had died in hospital as of Jan. 12, roughly a month after China abruptly dismantled its zero-COVID policy, according to government data.
But some experts said that figure probably vastly undercounts the full impact, as it excludes those who die at home, and because many doctors have said they are discouraged from citing COVID as a cause of death.

PHEIC
Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 20 Jan 2023

Confirmed cases :: 663 640 386
Confirmed deaths :: 6 713 093
Vaccine doses administered: 13 131 550 798

Weekly epidemiological update on COVID-19 - 19 January 2023

Overview
Globally, nearly 2.8 million new cases and over 13 000 deaths were reported in the week of 9 to 15 January 2023. In the last 28 days (19 December 2022 to 15 January 2023), nearly 13 million cases and almost 53 000 new deaths were reported globally – a decrease of 7% and an increase of 20%, respectively, compared to the previous 28 days. As of 15 January 2023, over 662 million confirmed cases and over 6.7 million deaths have been reported globally...

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 15 January 2023**

Note: Figure 1 does not yet include 59 938 COVID-19 related deaths announced by China for the period of 8 December 2022 to 12 January 2023.

**See Annex 1: Data, table, and figure note
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 21 Jan 2023

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

<table>
<thead>
<tr>
<th>Vaccines approved for use by at least one national regulatory authority</th>
<th>55</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines in WHO’s Emergency Use Listing</td>
<td>11</td>
</tr>
<tr>
<td>Doses shipped through COVAX to 146 countries</td>
<td>1.88bn</td>
</tr>
<tr>
<td>Reported vaccine price range per dose</td>
<td>$2 - $120</td>
</tr>
<tr>
<td>Doses secured globally</td>
<td>17.9bn</td>
</tr>
<tr>
<td>Novel oral antiviral therapeutic treatments arrived in 9 countries</td>
<td>46K</td>
</tr>
</tbody>
</table>

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 21 Jan 2023]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker – IMF

This tracker was last updated on May 5 2022. We have archived the information and will no longer provide updates.

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

Jan 21, 2023 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 124M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.2B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 390M

Other Delivered (Number of Doses): 430M

Total Delivered (Number of Doses): 830M

Total Administered (Number of Doses): 570M


https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 21 Jan 2023: https://data.covid19taskforce.com/data Notation: Last updated on: 02 Sep 2022 The global view below is complemented by country-specific dashboards here.

Our World in Data

:: 69.3% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.23 billion doses have been administered globally, and 1.19 million are now administered each day.
:: 26% of people in low-income countries have received at least one dose.

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries

Data updated on January 20th 2023

Country Category: Top 10 Donating Countries

United States: 85% shipped
China: 78% shipped
Germany: 68% shipped
France: 68% shipped
Spain: 55% shipped
United Kingdom: 46% shipped
Italy: 50% shipped
Japan: 69% shipped
Australia: 69% shipped
Canada: 55% shipped

Total Remaining
642,879,000

Total Shipped
1,371,263,610

Duke Global Health Innovation Center
**U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment**

**HHS**
*News*

No new digest content identified.

**FDA**
*Press Announcements*

**FDA Roundup: January 20, 2023**

On Thursday, the FDA announced the availability of a draft guidance titled, “Mpox: Development of Drugs and Biological Products”. The draft guidance provides the FDA's current thinking regarding nonclinical, virology, and clinical considerations for mpox (monkeypox) drug development programs. The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of mpox. Comments and suggestions regarding this draft guidance should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance.

**Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**
European Medicines Agency

News & Press Releases

News: Mandatory use of CTIS from 31 January 2023 for all new clinical trial applications (new)

Last updated: 19/01/2023

On 31 January 2023, the use of the Clinical Trials Information System (CTIS) will become mandatory for new clinical trial applications and will serve as the single-entry point for submission by sponsors and for regulatory assessment. This follows one year of transition, during which sponsors could choose whether to submit a new clinical trial application in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022...

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports [Selected]
Weekly COVID-19 country overview
Epidemiological update - 19 Jan 2023

Joint ECDC-WHO/Europe mpox (monkeypox) surveillance bulletin
Epidemiological update - 19 Jan 2023

Mpxox (formerly named monkeypox) situation update, as of 17 January 2023
Epidemiological update - 19 Jan 2023

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Africa CDC COVID-19 Vaccine Dashboard
Safeguarding Africa’s Health

Vaccine Overview  Vaccination Coverage  Vaccine Supply  Vaccine Utilization  Vaccine Policy  Vaccine Delivery Targets

Member State Vaccine Summary

1075.9M
Vaccine Doses Received

73%
% Doses Utilized

785.2M
Vaccine Doses Administered

44.9%
% Coverage (Fully Vaccinated)

(Last Update: December 31, 2022)
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on: 21 January 2023, 08:00 IST (GMT+5:30)
(↑ Status change since yesterday)

<table>
<thead>
<tr>
<th></th>
<th>Active (0.00%)</th>
<th>Discharged (98.81%)</th>
<th>Deaths (1.19%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1940</td>
<td>44149111</td>
<td>530730</td>
</tr>
</tbody>
</table>

Total Vaccination: 2,20,24,21,113 (2,07,067 ↑)

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

PHEIC
Mpx
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Multi-country outbreak of mpx, External situation report#14-19 January 2023
Polio this week as of 18 January 2023 - GPEI
:: This year, the polio programme is focusing on reaching zero-dose children (children who are either un- or under-immunized), in identified ‘consequential geographies’. But what exactly are consequential geographies, and why are they so vital to the global effort to eradicate polio? In this explanatory video, long-time polio eradicator and Director for polio eradication at WHO’s Eastern Mediterranean Region, Dr Hamid Jafari, explains more.

Summary of new polioviruses this week:
- Afghanistan: two WPV1 positive environmental samples
- Algeria: one cVDPV2 positive environmental sample
- Cameroon: one cVDPV2 case
- Chad: two cVDPV2 cases
- DR Congo: 16 cVDPV1 cases and 19 cVDPV2 cases
- Nigeria: one cVDPV2 case
- Somalia: one cVDPV2 case
- Zambia: two cVDPV2 positive environmental samples

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new digest content identified.

Northern Ethiopia
Ethiopia - Situation Report, 18 Jan 2023

Somalia
No new digest content identified.

Ukraine
Highlights Last Updated: 19 Dec 2022
**How well do development partners work together and follow country priorities to achieve the health SDGs?**

18 January 2023  *News release*

**Small Island Developing States accelerate action to tackle biggest killers**

17 January 2023  *Departmental news*

**8th WHO Technical Taskforce: Defeating Meningitis by 2030 -- A Global Road Map**

17 January 2023  *News release*

**WHO announces plans to establish a TB Vaccine Accelerator council**

The adverse impact of the COVID-19 pandemic on tuberculosis (TB) services has brought the urgency of vaccine development efforts into sharp focus. Speaking earlier today at a high-level panel on TB at the World Economic Forum, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced plans to establish a new TB Vaccine Accelerator Council.

The Council will facilitate the licensing and use of effective novel TB vaccines catalysing high-level alignment between funders, global agencies, governments and end users in identifying and overcoming barriers to TB vaccine development...

:::::

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region**

*No new digest content identified.*

**WHO Region of the Americas** PAHO

:: 19 Jan 2023

**UN Report: 131 million people in Latin America and the Caribbean cannot access a healthy diet**

The region has the highest cost for a healthy diet compared to the rest of the world, at USD 3.89 per person per day, while the world average is USD 3.54. January 19, 2023, Santiago, Chile. The new United Nations report Overview of Food Security and Nutrition 2022 finds that 22.5% of the Latin America and the Caribbean population cannot afford a...

:: 18 Jan 2023

**Small Island Developing States accelerate action to tackle biggest killers**

Barbados, 18 January 2023 -- The Government of Barbados, the World Health Organization (WHO) and the Pan American Health Organization are holding a high-level technical meeting on noncommunicable diseases (NCDs) and mental health with Small Island Developing States (SIDS). The discussion focuses on progress, challenges, and opportunities to...

:: 17 Jan 2023

**PAHO issues alert on outbreaks of avian influenza in birds in ten countries of the Americas**

Washington, DC, Jan. 17, 2023 (PAHO)- The Pan American Health Organization (PAHO) issued an alert in response to the increasing detection of avian influenza outbreaks in birds in ten countries in the Region of the Americas, and the recent confirmation of the first case of human infection of avian influenza A(H5) in South America. In an...

**WHO South-East Asia Region** SEARO
No new digest content identified.

**WHO European Region EURO**
:: 19 January 2023  News release
**2000 first responders trained in chemical preparedness and response in Ukraine**
:: 18 January 2023  News release

**WHO Collaborating Centre at UCL wins Outstanding Impact Prize from the Economic and Social Research Council**
:: 17 January 2023  News release
**Azerbaijan boosts its vaccine cold chain system**

**WHO Western Pacific Region**
No new digest content identified.

:::

**Disease Outbreak News (DONs)**
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

18 January 2023 | **Human infection caused by avian influenza A(H5) - Ecuador**

14 January 2023 | **Ebola disease caused by Sudan ebolavirus – Uganda**

:::

**New WHO Publications**
https://www.who.int/publications/i

*Selected Titles*
1 December 2023
**World Health Organization strategy (2022-2026) for the National Action Plan for Health Security**

20 January 2023
**Practical manual on tuberculosis laboratory strengthening, 2022 update**

20 January 2023
**WHO Drug Information - Volume 36, No. 4**

19 January 2023
**WHO Policy Brief: Gatherings in the context of COVID-19, 19 January 2023**

18 January 2023
**Operational manual on leishmaniasis vector control, surveillance, monitoring and evaluation**

16 January 2023
Sixteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTDs)

16 January 2023
Pilot decision workshop to aid prioritization of resources for malaria control in Ghana

CDC/ACIP [U.S.] [to 21 Jan 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases
Transcript for Vaccine Telebriefing
Friday, January 13, 2023

...Today, the CDC is publishing two reports that provide updated information about the impact of the COVID 19 pandemic on routine childhood immunizations, and that also highlight the importance of maintaining high vaccination coverage.

The first study shows that while overall vaccination rates among kindergarteners remain high, there were continued declines in vaccinations during the COVID 19 pandemic. During the 2021-2022 school year, National Vaccine vaccination coverage among kindergarten children dropped to 93%. This marks a one percentage point decline since the 2019-2020 school year, and a two percentage point drop since the start of the pandemic. While this might not sound significant, it means nearly 250,000 kindergarteners are potentially not protected against measles alone. And we know that measles, mumps and rubella vaccination coverage for kindergarteners is the lowest it has been in over a decade. This analysis is based on data collected by state and local immunization programs.

The second report shows that national coverage by age 24 months remained strong with most vaccines, and even increased among children born in 2018 and 2019, compared to those born in 2016 and 2017. This analysis is based on data from the National Immunization Survey child, or NIS-Child. While we continue to monitor the impact of the pandemic, we are encouraged that this report did not identify a national drop in vaccination coverage among children aged 24 months at the beginning of the pandemic.

However, these new findings also revealed persistent – and in some cases, widening – disparities in coverage. For example, the report found that coverage with the combined 7-vaccine series for children living below poverty or in rural areas decreased by four to five percentage points during the pandemic. The report also found the percentage of uninsured children not vaccinated by their second birthday was eight times that of privately insured children. These data add to previous research that highlights the impact of the COVID 19 pandemic on routine childhood vaccinations, as well as ongoing disparities in coverage...
Next ACIP Meeting: February 22-23, 2023

------

**MMWR Weekly**
January 20, 2023 / No. 3
[PDF of this issue][Selected content]

- Early and Increased Influenza Activity Among Children — Tennessee, 2022–23 Influenza Season
- Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022

------

**Coronavirus Disease 2019 (COVID-19)- CDC**
Announcements/reports/data summaries.
1/18/23

**Overall US COVID-19 Vaccine Distribution and Administration Update as of Wed, 18 Jan 2023 06:00:00 EST**

------

**Africa CDC**  [to 21 Jan 2023]
http://www.africacdc.org/
News
No new digest content identified.

------

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People’s Republic of China**  [to 21 Jan 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.
[Editor’s Note: The most recent post on this site is 24 Dec 2022, representing the last daily report on confirmed COVID-19 infections.]

**National Medical Products Administration – PRC**  [to 21 Jan 2023]
http://english.nmpa.gov.cn/
No new digest content identified.
[Editor’s Note: The most recent post on this site is 28 Dec 2022, and the last daily report on confirmed COVID-19 cases is dated 21 Dec 2022. These daily reports had been regular over the last year.]

China CDC  **Weekly Reports: Current Volume (5)**
Preplanned Studies: Transmission Dynamics and Epidemiological Characteristics of the SARS-CoV-2 Delta Variant — Hunan Province, China, 2021


Organization Announcements

Paul G. Allen Frontiers Group [to 21 Jan 2023]
https://alleninstitute.org/news-press/

No new digest content identified.

BMGF - Gates Foundation [to 21 Jan 2023]
https://www.gatesfoundation.org/ideas/media-center

Press Releases and Statements
Press release Jan 16, 2023

Gates Foundation CEO Announces Largest-Ever Annual Budget, Explains Foundation’s Approach to Fighting Poverty, Disease, and Inequity

SEATTLE, WA (January 16, 2023) – In his annual letter published today, Bill & Melinda Gates Foundation CEO Mark Suzman announced the foundation will spend US$8.3 billion this year to continue its work fighting poverty, disease, and inequity. He also shared examples of how the foundation uses its resources, voice, and convening power to call attention to and help find solutions for problems that otherwise might be neglected.

The budget—the largest in the foundation’s history—is a response to multiple crises that threaten to stall or reverse global progress on the Sustainable Development Goals since the start of the COVID-19 pandemic. These include war, economic turmoil, climate-related disasters, and large decreases in vaccinations for preventable infectious diseases, all of which have taken a significant toll on the world’s poorest people. The board of trustees’ approval of the budget puts the foundation on track to meet its commitment to reach an annual payout of US$9 billion by 2026—and represents a 15% increase over the 2022 forecasted payout.

“This is the toughest period for global health and development in recent memory, but in some ways, it’s also the reason we exist,” Suzman said. “To help meet the great needs ahead, we are doubling down on our commitment to our core mission: ensuring everyone can live a healthy and productive life.”

Bill & Melinda Gates Medical Research Institute [to 21 Jan 2023]
https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of
mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people.

News: Articles and Publications
No new digest content identified.

CARB-X  [to 21 Jan 2023]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 21 Jan 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.

CEPI – Coalition for Epidemic Preparedness Innovations  [to 21 Jan 2023]
http://cepi.net/
Latest News
CEPI and Institut Pasteur de Dakar announce 10-year partnership to boost manufacturing of affordable vaccines for the Global South
   CEPI will invest up to $50m in partnership to advance equitable access to routine and outbreak vaccines in Africa
News  19 Jan 2023

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
   CEPI to provide up to USD4.3 million (AUD6.4 million) to Vaxxas to advance development of its high-density microarray patch for mRNA vaccines.
News  17 Jan 2023

CEPI, Belgian universities to partner to enhance global pandemic preparedness
Organisations intend to collaborate in areas that will contribute to improved global pandemic preparedness, in particular with respect to KU Leuven’s VirusBank Platform and the University of Antwerp’s Vaccinopolis facility.
End Pandemics  16 Jan 2023

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 21 Jan 2023]
https://cioms.ch/
News; Publications; Events
Glossary of ICH terms and definitions
   This glossary combines the terms and definitions included in the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). It was
DARPA – Defense Advanced Research Projects Agency [U.S.] [to 21 Jan 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 21 Jan 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 21 Jan 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the
development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,
tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-
Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 21 Jan 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 21 Jan 2023]
http://www.euvaccine.eu/
Latest News, Events
News, Events
No new digest content identified.

Evidence Aid [to 21 Jan 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best
available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
Newborn health interventions in humanitarian settings
Added January 19, 2023
Fondation Merieux [to 21 Jan 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 21 Jan 2023]
https://www.gavi.org/
News Releases
19 January 2023
The US$ 500 million challenge: Gavi launches INFUSE 2.0 to scale up innovations in immunisation

19 January 2023
Gavi, Unilever Lifebuoy and The Power of Nutrition join forces in tripartite immunisation, handwashing and nutrition programme to tackle preventable diseases
- Gavi’s first multisectoral private sector partnership to include nutrition as part of holistic approach to disease prevention
- Groundbreaking partnership will raise awareness of the power of combining immunisation, handwashing with soap and nutrition to accelerate child survival efforts in Indonesia
- The US$ 8 million programme will reach over 1 million Indonesian children in areas with a high burden of malnutrition and vaccine-preventable diseases

GHIT Fund [to 21 Jan 2023]
https://www.ghitfund.org/newsroom/press
No new digest content identified.

Global Fund [to 21 Jan 2023]
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 21 Jan 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 21 Jan 2023]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.
IAVI statement on results from Mosaico HIV vaccine trial

... "IAVI would like to recognize Janssen, the study investigators, and the volunteers for their tremendous commitment to and impressive collaboration in conducting this large and complex efficacy trial,” said Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “A safe, effective, broadly accessible HIV vaccine remains an urgent global health priority. Going forward, IAVI and our collaborators believe that the most promising new HIV vaccine approaches are those intended to induce broadly neutralizing antibodies, and we are encouraged by recent scientific progress toward that goal.”...

International Coalition of Medicines Regulatory Authorities [ICMRA]

No new digest content identified.

IFFIm

No new digest content identified.

IFRC

No new digest content identified.
Press Releases [Selected]
No new digest content identified.

**Institut Pasteur** [to 21 Jan 2023]
Press Documents
No new digest content identified.

**ISC / International Science Council** [to 21 Jan 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Current
Blogs
**Global Risks 2023: The turbulent twenties, when risks collide**
18.01.2023

News
**Vacancy: The International Science Council is seeking a Science Director for its headquarters in Paris, France**
16.01.2023

**International Union of Immunological Societies (IUIS)**
https://iuis.org/
News/Events [Selected]
‘Viral Evolution and Evasion’, the 4th scientific session from BioNTech’s Global Scientific Exchange Program. - Event
Thursday 26th January 2023

**IVAC** [to 21 Jan 2023]
https://www.jhsph.edu/research CENTERS AND INSTITUTES/IVAC/index.html
Updates; Events
No new digest content identified.

**IVI** [to 21 Jan 2023]
http://www.ivi.int/
IVI News & Announcements
**2nd International Hepatitis E Symposium**
April 27-28, 2023 | Istanbul, Türkiye
Call for Abstracts
The 2nd International Hepatitis E Symposium will bring together leading experts in hepatitis E virus (HEV) research, presenting new data and updates on HEV, a serious though often neglected disease.
Over the course of this 2-day meeting, participants will engage in presentations, panels, and discussion around the latest findings in HEV epidemiology, diagnostics, and control. This symposium aims to promote scientific collaboration around the globe and advocate for HEV prevention efforts on the public health agenda.

Johns Hopkins Center for Health Security  [to 21 Jan 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
No new digest content identified.

MSF/Médecins Sans Frontières  [to 21 Jan 2023]
http://www.msf.org/
Latest  [Selected Announcements]
No new digest content identified.

National Academy of Medicine - USA  [to 21 Jan 2023]
https://nam.edu/programs/
News  [Selected]
No new digest content identified.

National Academy of Sciences - USA  [to 21 Jan 2023]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS  [to 21 Jan 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
NVAC 2023 Meetings
February 2-3, 2023  NVAC Meeting

NIH  [to 21 Jan 2023]
http://www.nih.gov/
News Releases
Experimental HIV vaccine regimen safe but ineffective, study finds
January 18, 2023 — The clinical trial began in 2019 and involved 3,900 volunteers.
An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined. The HPX3002/HVTN 706, or “Mosaico,” Phase 3 clinical trial began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America. Based on the DSMB’s recommendation, the study will be discontinued. Participants are being notified of the findings, and further analyses of the study data are planned.
Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, sponsored the Mosaico study with funding support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial was conducted by the NIAID-funded HIV Vaccine Clinical Trials Network, based at the Fred Hutchinson Cancer Research Center in Seattle. The U.S. Army Medical Research and Development Command provided additional study support...

**PATH** [to 21 Jan 2023]
https://www.path.org/media-center/
*Press Releases*
No new digest content identified.

**Rockefeller Foundation** [to 21 Jan 2023]
https://www.rockefellerfoundation.org/
*Selected Reports/Press Releases*
No new digest content identified.

**Sabin Vaccine Institute** [to 21 Jan 2023]
https://www.sabin.org/press/
*Latest News & Press Releases*
No new digest content identified.

**UNAIDS** [to 21 Jan 2023]
http://www.unaids.org/en
*Selected Press Releases/Reports/Statements*
No new digest content identified.

**UNICEF** [to 21 Jan 2023]
https://www.unicef.org/media/press-releases
*Press Releases, News Notes, Statements [Selected]*
No new digest content identified.

**Unitaid** [to 21 Jan 2023]
https://unitaid.org/
*Featured News*
No new digest content identified.

**Vaccine Equity Cooperative [nee Initiative]** [to 21 Jan 2023]
https://vaccineequitycooperative.org/news/
*News*
No new digest content identified.
Vaccination Acceptance & Demand Initiative [Sabin] [to 21 Jan 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 21 Jan 2023]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 21 Jan 2023]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 21 Jan 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
News
A policy framework for inclusive research design
18 January 2023
Dr Lilian Hunt, Equality, Diversity and Inclusion in Science and Health Lead at Wellcome, tells us about a framework to improve inclusive research policies and its potential impact on future research design.

News
Wellcome appoints new Director of Infectious Disease
18 January 2023
Alexander Pym, an infectious disease expert with experience across academia, clinical settings and industry, is to join Wellcome as our new Director of Infectious Disease.

The Wistar Institute [to 21 Jan 2023]
Media
Press Release Jan. 19, 2023
Wistar Institute HIV Researchers Win Grant to Explore Genetically Engineered Natural Killer Cells as HIV Therapy
PHILADELPHIA — (Jan. 19, 2023) — amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years.
WFPHA: World Federation of Public Health Associations [to 21 Jan 2023]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

World Medical Association [WMA] [to 21 Jan 2023]
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE) [to 21 Jan 2023]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

:::

ARM [Alliance for Regenerative Medicine] [to 21 Jan 2023]
Selected Press Releases
No new digest content identified.

BIO [to 21 Jan 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 21 Jan 2023]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 21 Jan 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA [to 21 Jan 2023]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.
The Time is Now: AMATA Calls for the rapid operationalisation of the African Medicines Agency and for regulatory system strengthening to be recognized as a key element of preparedness for future pandemics and post-pandemic recovery
Friday, 20 January 2023

PhRMA  [to 21 Jan 2023]
http://www.phrma.org/
Press Releases
No new digest content identified.

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases
Acquisition of Neogene Therapeutics completed
PUBLISHED 16 January 2023
AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).
Neogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US.

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases - No new digest announcements identified
Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnamon
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China --
-- SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements expected beginning in 2023 --
-- Expansion of Clover's mid- to late-stage pipeline expected starting in H1 2023, with a focus on (1) building a leading respiratory vaccine franchise and (2) establishing a presence in the pediatric vaccine market in China and the Asia Pacific --
Jan 16, 2023

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media - No new digest announcements identified

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
- Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV
- No vaccine-related safety issues identified
  LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706)
of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.

In light of the DSMB’s determination, the Mosaico clinical trial will be discontinued. Participant notifications and further analyses of the data are underway. Throughout the trial, study investigators have ensured that any individuals who contracted HIV received prompt HIV treatment and care.

“We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. “Though there have been significant advances in prevention since the beginning of the global epidemic, 1.5 million people acquired HIV in 2021 alone, underscoring the high unmet need for new options and why we have long worked to tackle this global health challenge. We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine. We are grateful to our Mosaico partners and the study investigators, staff and participants.”

Medicago

Merck

Moderna

Press Releases

Medicago

Media - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

17 January, 2023
Modern Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases

01.17.2023
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

Press Releases -- No new digest announcements identified
Serum Institute of India
NEWS & ANNOUNCEMENTS  -  No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News  -  No new digest announcements identified

Sinovac
Press Releases  -  No new digest announcements identified

SK Biosciences
Press Releases
SK bioscience Appoints New Executives to Accelerate New Growth Strategies
-  Two biopharmaceutical experts join SK bioscience to strengthen the future strategies - 2023.01.20

Takeda
Newsroom  -  No new digest announcements identified

Valneva
Press Releases  -  No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
Home  -  Website not responding [404 error]

WestVac Biopharma
Media
Rolling Out the 4th Shot! Coviccine® the 1st "COVID-19 Vaccine Booster" Administered in Chengdu
2023-01-13

On the morning of January 13, 2023, Coviccine®-Recombinant COVID-19 Vaccine (Sf9 cell) developed by WestVac Biopharma and West China Hospital of Sichuan University was first administered as a sequential booster following 3 doses of inactivated vaccine at the Northern Vaccination Site of Fangcao Community Health Service Centre in Chengdu High-Tech Industrial Development Zone, Sichuan Province...

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

:::::::
:::::::

Contents  [click to move among sections]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 1: E1-87
https://journalofethics.ama-assn.org/issue/segregation-health-care
Segregation in Health Care
Structural racism is deeply embedded in US health care. Legally sanctioned racial segregation in hospitals ended with the Civil Rights Act of 1964, with fiscally incentivized enforcement through Medicare payment structures implemented in 1966. Yet, practices such as sorting patients by insurance status still perpetuate de facto racial and class segregation, especially in academic health centers. This theme issue investigates a clear health justice demand to definitively end continued normalization of structural racism everywhere we care for our ill and injured. This issue considers sources of ethical, clinical, public health, and educational responsibilities to remediate health injustice where students and trainees learn their professions and internalize professional norms.
[Reviewed earlier]

American Journal of Infection Control
January 2023 Volume 51 Issue 1p1-120
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
January 2023 Volume 64 Issue 1p1-148
American Journal of Public Health
January 2023  113(1)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 6 (Dec 2022)
[Reviewed earlier]

Annals of Internal Medicine
January 2023  Volume 176, Issue 1
http://annals.org/aim/issue
Original Research
Monkeypox in Montréal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak
FREE
Luke B. Harrison, MD, PhD, Geneviève Bergeron, MD, MPH, Geneviève Cadieux, MD, PhD, ... et al.
Pages:67–76

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System A Population-Based Cohort Study
FREE
Scott Dryden-Peterson, MD, MSc, Andy Kim, BS, Arthur Y. Kim, MD, Ellen C. Caniglia, ScD, ... et al.
Pages:77–84

Reviews
Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review
FREE
Haley K. Holmer, PhD, MPH, Katherine Mackey, MD, MPP, Celia V. Fiordalisi, MS, and Mark Helfand, MD, MS
Pages:85–91

Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians
FREE
Isolde Sommer, MSc, MPH, PhD, Andreea Dobrescu, MD, PhD, Dominic Ledinger, MSc, MPH, ... et al.
Pages:92–104

Artificial Intelligence – An International Journal
COVID-19 vaccination during pregnancy: a systematic review and meta-analysis

SARS-CoV-2 exposure during pregnancy is related to adverse effects for both the mother and the infant. SARS-CoV-2 vaccination has lowered the risk of symptomatic disease substantially. Recently published studi...
Can uptake of childhood influenza immunisation through schools and GP practices be increased through behaviourally-informed invitation letters and reminders: two pragmatic randomized controlled trials

The UK is rolling out a national childhood influenza immunisation programme for children, delivered through primary care and schools. Behaviourally-informed letters and reminders have been successful at increa...

COVID-19 vaccine uptake and vaccine hesitancy in rural-to-urban migrant workers at the first round of COVID-19 vaccination in China

Migration can be linked to the transmission of COVID-19. COVID-19 vaccine uptake and hesitancy among rural-to-urban migrant workers in China, the largest group of internal migrants in the world, has not been c...

Deliberation, context, emotion and trust – understanding the dynamics of adults’ COVID-19 vaccination decisions in Germany

Willingness to vaccinate against coronavirus disease 2019 (COVID-19), which is vital to successful vaccination campaigns, is wavering and suboptimal. In Germany, quantitative research highlighted concerns rega...

BMC Research Notes

[No new digest content identified]
Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 1 Pages: 1-244 January 2023
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23 Issue 12 6 December 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 1—January 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 41 December 2022
https://www.sciencedirect.com/journal/epidemics/vol/41/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[New issue; No digest content identified]

Ethics & Human Research
Volume 44, Issue 6 Pages: 1-42 November–December 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Alzheimer disease biomarkers :: Payment to participate
[Reviewed earlier]
**Ethics & International Affairs**
Summer 2022 (36.2) | July 29, 2022

**ROUNDTABLE: VULNERABLE COMMUNITIES, FUTURE GENERATIONS, AND POLITICAL REPRESENTATION IN CLIMATE POLICY AND PRACTICE**

... This roundtable collection is motivated by the following question: How can the voices of vulnerable communities and future generations be adequately and fairly represented within climate change policy and practice? The contributions address this question from several perspectives. Simon Caney focuses on global governance institutions to protect the interests of future generations, considering specific proposals and asking what criteria should be used to evaluate them. Stephen Gardiner’s essay builds on his previous work calling for a global constitutional convention, elaborating on the proposal and addressing objections to it. Colin Hickey argues that it is necessary to consider more informal modes of representing vulnerable communities and future generations, such as through grassroots organizations. In our contribution, we argue that the interests of future generations are best represented in deliberations around climate policy and practice by those already most vulnerable to the impacts of climate change. Marco Grix and Krushil Watene’s essay argues that the representation of climate-vulnerable communities and future generations—in particular, Indigenous peoples—must ensure the protection of the complex network of social practices that guide how vulnerable communities respond to climate change...

**Ethics, Medicine and Public Health**
Volume 25  December 2022
[Reviewed earlier]

**The European Journal of Public Health**
Volume 32, Issue 6, December 2022
https://academic.oup.com/eurpub/issue/32/6
[Reviewed earlier]

**Expert Review of Vaccines**
Vol 22 (1) 2023  Issue In Progress
https://www.tandfonline.com/toc/ierv20/current
Review

**Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic**
Rontgene Solante, Carlos Alvarez-Moreno, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Sunate Chuenkitmongkol, D. V. Dung, Kao-Pin Hwang, Javier Ortiz Ibarra, Sasisopin Kiertiburanakul, Prasad S. Kulkarni, Christopher Lee, Ping-Ing Lee, Rommel Crisenio Lobo, Alejandro Macias, Cao Huu Nghia, Anna Lisa Ong-Lim, Alfonso J. Rodriguez-Morales, Rosana Richtmann, Marco Aurélio Palazzi Safadi, Hindra Irawan Satari & Guy Thwaites
Pages: 1-16
Published online: 11 Nov 2022
Foreign Affairs
Volume 101, Number 6   November/December 2022
https://www.foreignaffairs.com/issues/2022/101/6
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Volume 25, Issue 1  Pages A1-A10, 1-166 (January 2023)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/1
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 21 Jan 2023]
[No new digest content identified]

Global Health Action
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
December 2022 | Volume 10 | Number 6
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 21 Jan 2023]
[No new digest content identified]

Global Public Health
Volume 17, Issue 11 (2022)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]
Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 21 Jan 2023]
[No new digest content identified]

Health and Human Rights
Volume 24, Issue 2, December 2022
Special Section: COVID-19 Vaccine Equity and Human Rights
[Reviewed earlier]

Health Economics, Policy and Law
Volume 18 - Issue 1 - January 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 10, December 2022
https://academic.oup.com/heapol/issue/37/10
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 21 Jan 2023]
[No new digest content identified]

Human Gene Therapy
Volume 34, Issue 1-2 / January 2023
https://www.liebertpub.com/toc/hum/34/1-2
[New issue; No digest content identified]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]
**Immunity**
Jan 10, 2023 Volume 56 Issue 1 p1-224
https://www.cell.com/immunity/current
[Reviewed earlier]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/
[Accessed 21 Jan 2023]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjournal.com/content
[Accessed 21 Jan 2023]
[No new digest content identified]

**International Health**
Volume 14, Issue 6, November 2022
https://academic.oup.com/inthealth/issue/14/6
[Reviewed earlier]

**International Human Rights Law Review**
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol. 10 No. 1 (2023): January 2023
https://www.ijcmph.com/index.php/ijcmph/issue/view/96
[Reviewed earlier]

**International Journal of Epidemiology**
Volume 51, Issue 6, December 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

**International Journal of Human Rights in Healthcare**
Volume 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
Special Issue: Children, young people and their international human right to healthcare
[Reviewed earlier]

JAMA
January 17, 2023, Vol 329, No. 3, Pages 195-268
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]

JAMA Health Forum
January 2023, Vol 4, No. 1
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
January 2023, Vol 177, No. 1, Pages 3-104
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
January 2023 - Volume 21 - Issue 1
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
Evidence Syntheses
Absorptive capacity in the adoption of innovations in health: a scoping review
Godfrey, Christina M.; Kircher, Colleen; Ashoor, Huda M.; More

Journal of Adolescent Health
February 2023  Volume 72  Issue 2  p161-314
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 6, December 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-6
[Reviewed earlier]
Journal of Development Economics
Volume 160  January 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
*Ethical Issues using Digital Surveillance Technologies in Research*
[Reviewed earlier]

Journal of Epidemiology & Community Health
December 2022 - Volume 76 - 12
https://jech.bmj.com/content/76/12
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 4  Pages: 315-424  December 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 2, 2022
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 4, November 2022
https://muse.jhu.edu/issue/48371
*Table of Contents*
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 1, February 2023
*Contents*
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Sustainability and Resilience in Migration Governance for a Post-pandemic World
Anna Triandafyllidou & Brenda S. A. Yeoh
Pages: 1-14
Published online: 06 Jan 2023

Journal of Infectious Diseases
Volume 226, Issue 10, 15 November 2022
https://academic.oup.com/jid/issue/226/10
[Reviewed earlier]

Journal of International Development
Volume 35, Issue 1 Pages: 1-197 January 2023
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
January 2023 - Volume 49 - 1
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
January 2023 Volume 252 p1-226
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 21 Jan 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
January/February 2023 - Volume 29 - Issue 1
https://journals.lww.com/jphmp/pages/currenttoc.aspx
Editorial

Incorporating a Health Equity Lens Into Surveillance Information Systems: Opportunities and Challenges
Martin, Erika G.; Angles, John S.

Journal of Public Health Policy
Volume 43, issue 4, December 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-4
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
January 2023 Volume 20 Issue 198
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 29, Issue 8, December 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96 Number 24 December 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Jan 21, 2023 Volume 401 Number 10372 p169-244, e2-e3
https://www.thelancet.com/journals/lancet/issue/current

Editorial

One Health: a call for ecological equity
The Lancet

The Lancet Child & Adolescent Health
Jan 2023 Volume 7 Number 1 p1-76, e1
https://www.thelancet.com/journals/lanchi/issue/current
Lancet Digital Health
Jan 2023  Volume 5  Number 1  e1-e50
https://www.thelancet.com/journals/landig/issue/current

Lancet Global Health
Jan 2023  Volume 11  Number 1  e1-e169
https://www.thelancet.com/journals/langlo/issue/current

Lancet Infectious Diseases
Jan 2023  Volume 23  Number 1  p1-130, e1-e46
https://www.thelancet.com/journals/laninf/issue/current

Lancet Public Health
Jan 2023  Volume 8  Number 1  e1-e84
https://www.thelancet.com/journals/lanpub/issue/current

Lancet Respiratory Medicine
Jan 2023  Volume 11  Number 1  p1-110, e1-e11
https://www.thelancet.com/journals/lanres/issue/current

Maternal and Child Health Journal
Volume 26, issue 12, December 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-12

Medical Decision Making (MDM)
Volume 43 Issue 1, January 2023
http://mdm.sagepub.com/content/current

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 100, Issue 4  Pages: 963-1278  December 2022
**Nature**
Volume 613 Issue 7944, 19 January 2023
https://www.nature.com/nature/volumes/613/issues/7944

*Article*  Open Access 11 Jan 2023

Financial incentives for vaccination do not have negative unintended consequences

Findings from large-scale studies in Sweden and the USA indicate that providing financial incentives for vaccination and informing about state incentive programmes do not have any negative unintended consequences.

Florian H. Schneider, Pol Campos-Mercade, Armando N. Meier

---

**Nature Biotechnology**
Volume 41 Issue 1, January 2023
https://www.nature.com/nbt/volumes/41/issues/1

*Editorial*  18 Jan 2023

The next giant step for microbes

A microbiome therapy is approved by the FDA for treatment of Clostridioides difficile. What’s next?

---

**Nature Communications**
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 21 Jan 2023)

[No new digest content identified]

---

**Nature Genetics**
Volume 55 Issue 1, January 2023
https://www.nature.com/ng/volumes/55/issues/1

*Article*  15 Dec 2022

Human genetic diversity alters off-target outcomes of therapeutic gene editing

CRISPRme is an off-target nomination tool that accounts for human genetic diversity. Ancestry-dependent allele-specific off-target edits can occur with therapies currently in clinical trials, highlighting the importance of genetic variation-aware assessment.

Samuele Cancellieri, Jing Zeng, Luca Pinello

*Article*  12 Dec 2022

Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases

Genome-wide association studies comprising 1,091 metabolites and 309 metabolite ratios in 8,299 individuals from the Canadian Longitudinal Study on Aging provide insights into the genetic architecture of metabolites and their role in human diseases.

Yiheng Chen, Tianyuan Lu, J. Brent Richards
Nature Human Behaviour
Volume 6 Issue 12, December 2022
https://www.nature.com/nathumbehav/volumes/6/issues/12
[Reviewed earlier]

Nature Medicine
Volume 28 Issue 12, December 2022
https://www.nature.com/nm/volumes/28/issues/12
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 22 Issue 1, January 2023
https://www.nature.com/nrd/volumes/22/issues/1
[Reviewed earlier]

Nature Reviews Genetics
Volume 24 Issue 1, January 2023
https://www.nature.com/nrg/volumes/24/issues/1
[Reviewed earlier]

Nature Reviews Immunology
Volume 23 Issue 1, January 2023
https://www.nature.com/nri/volumes/23/issues/1
[Reviewed earlier]

New England Journal of Medicine
January 19, 2023  Vol. 388 No. 3
https://www.nejm.org/toc/nejm/medical-journal
Original Articles
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
P. Winokur and Others

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 21 Jan 2023]
Articles
[No new digest content identified]

Pediatrics
Volume 151, Issue 1  January 2023
https://publications.aap.org/pediatrics/issue/151/1
PharmacoEconomics
Volume 40, issue 12, December 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-12
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 21 Jan 2023)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 21 Jan 2023)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 21 Jan 2023)
Essential childhood immunization in 43 low- and middle-income countries: Analysis of spatial trends and socioeconomic inequalities in vaccine coverage
Anna Dimitrova, Gabriel Carrasco-Escobar, Robin Richardson, Tarik Benmarhnia
Research Article | published 17 Jan 2023 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004166

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 21 Jan 2023)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 21 Jan 2023]
Research Article
Attitudes, perceptions, and preferences towards SARS CoV-2 testing and vaccination among African American and Hispanic public housing residents, New York City: 2020–2021
Chigozirim Izeogu, Emily Gill, Kaitlyn Van Allen, Natasha Williams, Lorna E. Thorpe, Donna Shelley
Research Article | published 19 Jan 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0280460
Knowledge, attitudes, and practices towards HPV vaccination among reproductive age women in a HIV hotspot in the US
Aasith Villavicencio, Gray Kelsey, Nicholas F. Nogueira, Julia Zukerberg, Ana S. Salazar, Lucila Hernandez, Patricia Raccamarich, Maria Luisa Alcaide
Research Article | published 19 Jan 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0275141

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 21 Jan 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
January 10, 2023 | vol. 120 | no. 2
https://www.pnas.org/toc/pnas/120/2
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 166 January 2023
[Reviewed earlier]

Proceedings of the Royal Society B
11 January 2023  Volume 290  Issue 1990
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 213  Pages 1-198 (December 2022)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]
Public Health Reports
Volume 137 Issue 6, November/December 2022
https://journals.sagepub.com/toc/phrg/137/6
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 1-2, January 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 19 Issue 1, January 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 21 Jan 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
18 Jan 2023
Genomic surveillance and sequencing of SARS-CoV-2 across South America
Opinion and analysis | English |

18 Jan 2023
A review of immunization legislation for children in English- and Dutch-speaking Caribbean countries
Original research | English |

Risk Analysis
Volume 42, Issue 11 Pages: 2345-2606 November 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Special issue title: Risk Communication During Crises and Chronic Exposures
[Reviewed earlier]

Risk Management and Healthcare Policy
Remaking the Chinese Academy of Sciences
BY Xiyi Yang, Xiaoyu Zhou, Cong Cao
19 Jan 2023: 240-243
Under pressure to reinvent itself, the CAS should concentrate on managing large-scale research infrastructures

Science and Engineering Ethics
Volume 28, issue 6, December 2022
[Reviewed earlier]

Science Translational Medicine
Volume 15| Issue 679| 18 Jan 2023
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Social Science & Medicine
Volume 314  December 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 21 Jan 2023]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 43, issue 5-6, December 2022
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 51  January–February 2023
Zero by 2030 and OneHealth: The multidisciplinary challenges of rabies control and elimination
D. Katterine Bonilla-Aldana, Julian Ruiz-Saenz, Marlen Martinez-Gutierrez, Wilmer Villamil-Gomez, ... Alfonso J. Rodriguez-Morales
Article 102509

Tropical Medicine & International Health
Volume 28, Issue 1 Pages: i-iv, 1-70 January 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 41, Issue 1 Pages 1-284 (4 January 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/1

Selected Content
Discussion  Full text access
“I won’t be a guinea pig”: Rethinking public health communication and vaccine hesitancy in the context of COVID-19
S. Michelle Driedger, Gabriela Capurro, Jordan Tustin, Cindy G. Jardine
Pages 1-4

Review article  Open access
Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping review
A. Lip, M. Pateman, M.M. Fullerton, H.M. Chen, ... C. Constantinescu
Pages 23-35

Research article  Full text access
COVID-19 vaccine coverage disparities in rural and farm children
Jeffrey J. VanWormer, Gabriella Alicea, Bryan P. Weichelt, Richard L. Berg, Maria E. Sundaram
Pages 68-75

Research article  Full text access
Misinformation and COVID-19 vaccine hesitancy
Tara Zimmerman, Kristina Shiroma, Kenneth R. Fleischmann, Bo Xie, ... Min Kyung Lee
Pages 136-144

Research article  Open access
Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria
C. Edson Utazi, Justice M.K. Aheto, Adelle Wigley, Natalia Tejedor-Garavito, ... Felicity T. Cutts
Pages 170-181
Spirituality is associated with Covid-19 vaccination scepticism
Natalia Zarzeczna, Tisa Bertlich, Bojana Večkalov, Bastiaan T. Rutjens
Pages 226-235

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 21 Jan 2023]
Latest Articles
Open Access Article
Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action
by Ramy Mohamed Ghazy

Open Access Article
The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as a Case Study
by Manuela Di Fusco

Value in Health
January 2023 Volume 26 Issue 1p1-150
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
Research Article metrics
Revised
Learning from success cases: ecological analysis of potential pathways to universal access to family planning care in low- and middle-income countries. [version 3; peer review: 1 approved, 1 approved with reservations]
Franciele Hellwig, Aluisio JD Barros
Peer Reviewers Carmen Simone Grilo Diniz; Lynne Gaffikin
Background: Development assistance for health (DAH) is an important mechanism for funding and technical support to low-income countries. Despite increased DAH spending, intractable health challenges remain. Recent decades have seen numerous efforts to reform DAH models, yet pernicious challenges persist amidst structural complexities and a growing number of actors. Systems-based approaches are promising for understanding these types of complex adaptive systems. This paper presents a systems-based understanding of DAH, including barriers to achieving sustainable and effective country-driven models for technical assistance and capacity strengthening to achieve better outcomes.

**Immunogenicity, Safety and Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA Vaccination in Immunocompromised Adolescents and Young Adults: A systematic Review and Meta-Analyses**

Patrick DMC Katoto, Mireille AM Kakubu, Jacques L Tamuzi, Amanda S Brand, Adaeze Ayuk, Liliane N. Byamungu, Charles Shely Wiysonge, Glenda Gray
medRxiv 2023.01.20.23284812; doi: https://doi.org/10.1101/2023.01.20.23284812

**The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5**

Sithichai Kanokudom, Jira Chansaeenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratcadawan Aeemjinda, Nongkanok Khanarat, Preeyporn Vichaiwattana, Sirapa Klinfung, Thanunrat Thongme, Donchida Srimuan, Thaksaporn Thatsanatorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan
medRxiv 2023.01.19.23284761; doi: https://doi.org/10.1101/2023.01.19.23284761
Emergency care interventions for pediatric severe acute respiratory infections in low- and middle-income countries: a systematic review and narrative synthesis
Pryanka Relan, Stephanie Chow Garbern, Gerard O'Reilly, Corey B Bills, Megan Schultz, Sean Kivlehan, Indi Trehan, Torben K Becker
medRxiv 2023.01.19.23284769; doi: https://doi.org/10.1101/2023.01.19.23284769

Online randomised trials with children: A scoping review
Simone Lepage, Aislinn Conway, Noah Goodson, Paul Wicks, Laura Flight, Declan Devane
Paediatric trials must contend with many challenges that adult trials face but often bring additional obstacles. Decentralised trials, where some or all trial methods occur away from a centralised location, are a promising strategy to help meet these challenges. This scoping review aims to (a) identify what methods and tools have been used to create and conduct entirely online-decentralised trials with children and (b) determine the gaps in the knowledge in this field. This review will describe the methods used in these trials to identify their facilitators and the gaps in the knowledge.

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 06 Jan 2023]
[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
Research Ethics Review of Patient-Oriented Research: Perspectives of Researchers and Research Ethics Boards
Dawn P. Richards, et al.
Last edited: Jan 18, 2023 UTC
Medicine and Health Sciences Other Medicine and Health Sciences
Background: Patient-oriented research (POR) incorporates patient partners as members of a research team. With the strengths and challenges of POR starting to emerge, one challenge we explore here is the research ethics application and review stages.
OSF Preprints

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
Systematic Review Open Access
Model systems informing mechanisms and drug discovery: a systematic review of POLG-related disease models [version 1; peer review: awaiting peer review]
Jonathan Meyrick, Renae J Stefanetti, Linda Errington, Robert McFarland, Gráinne S. Gorman, Nichola Z. Lax
Introduction
Pathogenic variants in the gene encoding the catalytic subunit of DNA polymerase gamma (POLG), comprise an important single-gene cause of inherited mitochondrial disorders. Clinical manifestations are now recognised as an array of overlapping clinical features rather than discrete syndromes as originally conceptualised. Animal and cellular models have been used to address numerous scientific questions, from basic science to the development and assessment of novel therapies. Here, we sought
to perform a systematic review of the existing models used in mitochondrial research and their effectiveness in recapitulating POLG-related disease.

*Study Protocol Open Access*

**Understanding the epidemiology of iNTS disease in Africa in preparation for future iNTS-vaccine studies in endemic countries: Seroepidemiology in Africa of iNTS (SAiNTS) Study Protocol** [Version 9.0] [version 1; peer review: awaiting peer review]
Helen Dale, et al. for Vacc-INTS

*Research Article Open Access*

**Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples** [version 1; peer review: awaiting peer review]
Muzamil Mahdi Abdel Hamid, et al.

**Abstract**
We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations...

* * *

**Think Tanks**

**Brookings** [to 21 Jan 2023]
http://www.brookings.edu/

**Latest Research [Selected]**
No new digest content identified.

**Center for Global Development** [to 21 Jan 2023]
https://www.cgdev.org/

**All Research [Selected]**

**CGD NOTES**

**The Future of Global Health Spending Amidst Multiple Crises**
Amanda Glassman et al.
January 17, 2023
This CGD note summarizes the implications of the macroeconomic context and broader financing outlook for domestic and external health spending and proposes a “menu” of policy options to keep health spending on track and blunt negative impacts on health systems and population health around the world.

**Chatham House** [to 21 Jan 2023]
https://www.chathamhouse.org/

**Selected Analysis, Comment**
No new digest content identified.
No new digest content identified.

Kaiser Family Foundation [to 21 Jan 2023]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute
https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 21 Jan 2023]
Publications [Selected]
No new digest content identified.

Pew Research Center [to 21 Jan 2023]
https://www.pewresearch.org/
Latest Publications [Selected]
No new digest content identified.

Rand [to 21 Jan 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
No new digest content identified.

Urban Institute [to 21 Jan 2023]
https://www.urban.org/publications
New Research Publications - Selected

World Economic Forum [to 21 Jan 2023]
https://agenda.weforum.org/news/
Media
News 19 Jan 2023
New 100-Day Goal Set for Faster, Equitable Pandemic Response
39 Organizations Pledge to Close Gaps on Global Health Equity

* * * * *

* * * *

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *

* * * * *